2023年9月15日 · BARCELONA, Spain. September, 15 th 2023 - Almirall S.A. (BME: ALM) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the marketing authorization of EBGLYSS (lebrikizumab) for the treatment of adult and adolescent patients (12 years and …

EBGLYSS (lebrikizumab) for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate-to-severe atopic dermatitis (AD), who are candidates for systemic therapy. Almirall will first start the commercial launch in Germany. The company will continue the rollout in further European

BARCELONA, Spain. November 17 th, 2023 – Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, announced today that the European Commission (EC) has approved EBGLYSS (lebrikizumab) for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate-to …

2024年9月25日 · Patients taking EBGLYSS who completed any of the parent studies (ADvocate 1 and 2, ADhere, ADore, ADopt-VA) were able to enroll in ADjoin. The ADhere parent study includes patients taking topical corticosteroids with EBGLYSS as a combination therapy. Patients could also enroll directly into ADjoin without participating in a parent study.

BARCELONA, Spain. October 28, 2022 –Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today announced that the European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for lebrikizumab for the treatment of moderate to severe atopic dermatitis.

2024年5月1日 · The Decision Forum has decided that lebrikizumab (EBGLYSS) should be introduced for the treatment of severe atopic dermatitis (AD) in adults and adolescents aged 12 years and older with a body weight of at least 40 kg who are eligible for systemic treatment. 3. The pharmaceutical company Almirall starts the Nordic launch in Norway.

2023年9月15日 · (EMA) issued a positive opinion recommending the marketing authorization of EBGLYSS (lebrikizumab) for the treatment of adult and adolescent patients (12 years and older with a body weight of at least 40 kg) with moderate-to-severe atopic dermatitis, who are candidates for systemic therapy.

Uxbridge, UK. 10 th July 2024 – Almirall S.A. (BME: ALM), a global biopharmaceutical company dedicated to medical dermatology, announced today that the National Institute for Health and Care Excellence (NICE) has recommended Ebglyss (lebrikizumab) for use in moderate to severe Atopic Dermatitis in the NHS England.

Ebglyss® (atopic dermatitis) Expanding growth, as we execute rollouts in new countries. 9M 2024 net sales €20.4 MM. Klisyri® (actinic keratosis) Improving market share in main countries. Wynzora® (psoriasis) Steady growth pattern across multiple regions. Klisyri® (large field) US large field launched in August 2024. EU launch expected in ...

2024年7月22日 · The planned launches of Ebglyss in other European markets (Austria, Denmark, and Spain) before the end of 2024 are on track. Ilumetri®, for the treatment of psoriasis, continued to show very strong results, with sales reaching €100.5 MM in H1, which represents a 25% increase YoY.